A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Phase 2

Kinevant Sciences GmbH